The potential of therapeutic strategies targeting mitochondrial biogenesis for the treatment of insulin resistance and type 2 diabetes mellitus

被引:0
作者
Wenwen Ding
Xiaoxue Yang
Kaiyi Lai
Yu Jiang
Ying Liu
机构
[1] Beijing University of Chinese Medicine,School of Life Sciences
[2] University of Pittsburgh,Department of Pharmacology and Chemical Biology, School of Medicine
来源
Archives of Pharmacal Research | 2024年 / 47卷
关键词
Mitochondrial biogenesis; Type 2 diabetes mellitus; Diabetic complications; Insulin resistance; Natural products;
D O I
暂无
中图分类号
学科分类号
摘要
Type 2 diabetes mellitus (T2DM) is a persistent metabolic disorder marked by deficiencies in insulin secretion and/or function, affecting various tissues and organs and leading to numerous complications. Mitochondrial biogenesis, the process by which cells generate new mitochondria utilizing existing ones plays a crucial role in energy homeostasis, glucose metabolism, and lipid handling. Recent evidence suggests that promoting mitochondrial biogenesis can alleviate insulin resistance in the liver, adipose tissue, and skeletal muscle while improving pancreatic β-cell function. Moreover, enhanced mitochondrial biogenesis has been shown to ameliorate T2DM symptoms and may contribute to therapeutic effects for the treatment of diabetic nephropathy, cardiomyopathy, retinopathy, and neuropathy. This review summarizes the intricate connection between mitochondrial biogenesis and T2DM, highlighting the potential of novel therapeutic strategies targeting mitochondrial biogenesis for T2DM treatment and its associated complications. It also discusses several natural products that exhibit beneficial effects on T2DM by promoting mitochondrial biogenesis.
引用
收藏
页码:219 / 248
页数:29
相关论文
共 1413 条
[51]  
Blankenburg M(2022)Effect of bedtime melatonin administration in patients with type 2 diabetes: a triple-blind, placebo-controlled, randomized trial Pharmacol Res 178 106028-275
[52]  
Kraemer N(2020)Inhibition of mitochondrial fission by Drp-1 blockade by short-term leptin and Mdivi-1 treatment improves white adipose tissue abnormalities in obesity and diabetes Biomolecules 10 347-2981
[53]  
Hirschfeld G(2006)The role of PGC-1alpha and mitochondrial biogenesis in kidney diseases Diabetes 55 273-83
[54]  
Krumova EK(2022)Adipose overexpression of phosphoenolpyruvate carboxykinase leads to high susceptibility to diet-induced insulin resistance and obesity Dis Model Mech 15 dmm049223-11925
[55]  
Maier C(2015)Adipose tissue-specific ablation of PGC-1beta impairs thermogenesis in brown fat Nat Commun 6 10210-61
[56]  
Hechler T(2016)The transcriptional coregulator PGC-1beta controls mitochondrial function and anti-oxidant defence in skeletal muscles Diabetes Obes Metab 18 641-S148
[57]  
Aksu F(2014)Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? EMBO Mol Med 6 580-1046
[58]  
Magerl W(2009)Mitochondrial response to nutrient availability and its role in metabolic disease Cancer Lett 284 1-169
[59]  
Reinehr T(2022)Resveratrol and chemoprevention Int J Biol Sci 18 826-748
[60]  
Wiesel T(2016)Neuraminidase 1 deficiency attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory via AMPK-SIRT3 pathway in diabetic cardiomyopathy mice Curr Diab Rep 16 61-2029